Oncolys BioPharma Inc.
Notice of Initiation of Dosing in Clinical Trial Aiming for a New Indication for Telomelysin® Injection, an Oncolytic Virus
Dosing of the first patient has started in a Phase 1b/2a clinical trial of Telomelysin® injection targeting lower rectal cancer and anal cancer. The trial evaluates the efficacy and safety of Telomelysin® injection combined with preoperative chemoradiotherapy for local tumors. The aim is to contribute to a clinical approach that avoids stoma creation. Impact on the fiscal year ending December 2026 is expected to be minimal (unspecified).
Key Figures
- Fiscal year ending December 2026: Unknown
- Clinical trial start: First patient dosed
- Related therapy name: Telomelysin® injection (OBP-301)
AI要約
Business and R&D Latest Developments
Oncolys BioPharma Inc. has initiated a Phase 1b/2a clinical trial aiming for a new indication of the oncolytic virus Telomelysin® injection (OBP-301). This trial targets lower rectal cancer and anal cancer and will evaluate the efficacy and safety of Telomelysin® injection in combination with preoperative chemoradiotherapy for local tumors. The objective is to potentially contribute to a care pathway that avoids stoma creation.
Financial Impact and Outlook
The impact on the fiscal results for the fiscal year ending December 2026 is considered minimal; however, specific amounts and timing are unspecified. Progress in the clinical trial is an important step toward broader therapeutic application and may affect medium- to long-term business growth.
Oncolys BioPharma Inc.
Company overview · Stock price · Financial data · All IR
